FDA regenerative medicine approvals show growing momentum
Regenerative medicine offers an innovative approach to treating different indications by restoring damaged or diseased cells and tissues.
Drug Development
FDA grants fast track designation for HAYA Therapeutics’ HTX-001
Eisai and CORE Biomedicine agree on global licence for oncology pipeline
BioMarin and n-Lorem partner on early research for ReNU syndrome therapy
Argenx signs agreement to buy Forte Biosciences for $2.2bn
Biointron introduces RushData platform for AI-driven antibody discovery
Kenvue’s Tylenol with Naproxen gains FDA approval
BeOne to invest $300m in US manufacturing facility expansion
